Zusammenfassung
Die Verordnungen der Antianämika erstrecken sich auf Eisenpräparate, Folsäure, Folsäurekombinationen und Epoetinpräparate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
American Medical Association (1986): Drug evaluations (6th Edition). Saunders Company Philadelphia, London, pp. 589–601.
Arzneimittelbrief (2002): Arzneitherapien an der Obergrenze der finanziellen Belastbarkeit (Teil 1). Beispiele Erythropoietin und i.v. Immunglobuline in der Hämatologie/Onkologie. 36: 25–29.
Arzneimittelbrief (2003): Wirksamkeit von rekombinantem Erythropoitin (rhEPO) bei schwerkranken Patienten auf Intensivstationen.: 37:29–30.
Arzneimittel-Richtlinien (2002): Epoetin zur Behandlung der Anämie bei Patienten mit soliden Tumoren, malignen Lymphomen und Plasmozytom (z. B. Erypo; NeoRecormon). Dtsch Ärztebl 99: C2129–C2130.
Baker WF, Bick RL (1999): Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 25: 387–406.
Bamonti-Catena F, Buccianti G, Porcella A, Valenti G, Como G et al (1999): Folate measurements in patients on regular hemodalysis treatment. Am J Kidney Dis 33:492–497.
Begemann H, Rastetter J (Hrsg) (1993): Klinische Hämatologie, Kapitel „Anämien“. Georg-Thieme-Verlag Stuttgart, New York, S. 237–418.
Besarab A, Bolton WK, Browne JK, Egrie, JC, Nissenson AR et al (1998): The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590.
Büchner T (2003): Anämien. In: Therapie Innerer Krankheiten (Hrsg Paumgartner G, Steinbeck G). Springer-Verlag Berlin, Heidelberg, New York, 10. Aufl., S. 1015.
Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J et al (2002): Pure red-cell aplasia and antierythropietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475.
Collins AJ, Ma JZ, Xia A, Ebben J (1998): Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32(Suppl 4): S133–S141.
Czeisel AE, Dudas I (1992): Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832–1835.
Dührsen U (2002): Gibt es Indikationen für Erythropoetin in der Onkologie? Dtsch Ärztebl 99: A3470–A3475.
Eckardt KU (1998): Erythropoietin, Karriere eines Hormons. Dtsch Ärztebl 95: A-285–290.
Eckardt KU, Casadevall N (2003): Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18: 865–869.
Fishbane S, Mittal SK, Maesaka JK (1999): Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55: 67–70.
Forth W, Rummel W, Wollenberg P (2001): Pharmakotherapie des Eisenmangels. In: Allgemeine und spezielle Pharmakologie und Toxikologie (Hrsg Forth W, Henschler D, Rummel W, Förstermann U, Starke K). Urban & Fischer Verlag München, Jena, 8. Aufl., S. 739–749.
Hanley DF (2004): The challenge of stroke prevention. JAMA 291: 621–622.
Heinrich HC (1986): Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)-und Eisen(III)-Präparate. Dtsch Apoth Ztg 126: 681–690.
Homocysteine Studies Collaboration (2002): Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022.
Ibbotson T, Goa KL (2001): Darbepoetin alfa. Drugs 61:2097–2104.
Kaltwasser JP (2003): Eisenmangelanämie. In: Berdel WE, Böhm M, Classen M, Diehl V, Kochsiek K, Schmigel W (Hrsg): Innere Medizin. 5. Auflage, Urban & Fischer, München Jena, S. 706–711.
Kaltwasser JP, Werner E, Niechzial M (1987): Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneim Forsch 37:122–129.
Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG et al (1998): Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578–583.
Koletzko B, Pietrzik K (2004): Gesundheitliche Bedeutung der Folsäure. Dtsch Ärztebl 101: A 1670–1681.
Lange H, Suryapranata H, De Luca G, Böner C, Dille J et al (2004): Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673–2681.
MacDougall IC (1999): Strategies for iron supplementation: Oral versus intravenous. Kidney Int 55: 61–66.
Marcus R, Coulston AM (1996): The Vitamins. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 9th edition. McGraw-Hill, New York, pp. 1547–1553.
Marsh WA, Rascati KL (1999): Meta-analyses of the effectiveness of erythropoetin for end-stage renal disease and cancer. Clin Ther 21:1443–1455.
O’Riordan E, Foley RN (2001): When should we start erythropoietin therapy? Nephrol Dial Transplant 16:891–892.
Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL et al (2004): Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 350:134–142.
Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL et al (2001): Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204–1214.
Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC et al (2004): Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarktion, and death: the vitamin intervention for stroke prevention (VISP). JAMA 291: 565–575.
Wald NJ (2004): Folic acid and the prevention of neural-tube defects. N Engl J Med 350:101–103.
Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000): The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ß: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15: 2014–2019.
Wooltorton E (2002): Epoetin alfa (Eprex): reports of pure red cell aplasia. Can Med Assoc J 166: 480.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mengel, K., Schmidt, H. (2004). Antianämika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-18513-7_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21359-8
Online ISBN: 978-3-642-18513-7
eBook Packages: Springer Book Archive